Vistagen Therapeutics IncNASDAQ:VTGN
- LAST PRICE4.4001
- TODAY'S CHANGE (%)-0.0799 (-1.7835%)
- Bid / Lots4.3900/ 8
- Ask / Lots4.4100/ 2
- Open / Previous Close4.4800 / 4.4800
- Day Range
- 52 Week Range
- Volume92,212
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTGN |
|---|---|---|
| 09:32 ET | 911 | 4.48 |
| 09:36 ET | 200 | 4.5 |
| 09:38 ET | 285 | 4.4828 |
| 09:39 ET | 342 | 4.49 |
| 09:41 ET | 562 | 4.525 |
| 09:43 ET | 100 | 4.49 |
| 09:48 ET | 300 | 4.5 |
| 09:50 ET | 160 | 4.49 |
| 09:52 ET | 1000 | 4.49 |
| 09:54 ET | 3902 | 4.5044 |
| 09:56 ET | 2400 | 4.515 |
| 10:01 ET | 759 | 4.51 |
| 10:03 ET | 100 | 4.49 |
| 10:08 ET | 1700 | 4.48 |
| 10:10 ET | 1100 | 4.42 |
| 10:15 ET | 300 | 4.45 |
| 10:19 ET | 291 | 4.44 |
| 10:24 ET | 3024 | 4.37 |
| 10:26 ET | 5214 | 4.385 |
| 10:28 ET | 500 | 4.38 |
| 10:33 ET | 300 | 4.38 |
| 10:37 ET | 100 | 4.395 |
| 10:42 ET | 477 | 4.4 |
| 10:44 ET | 325 | 4.4068 |
| 10:46 ET | 343 | 4.4 |
| 10:48 ET | 200 | 4.39 |
| 10:55 ET | 200 | 4.36 |
| 10:57 ET | 100 | 4.38 |
| 11:06 ET | 100 | 4.3799 |
| 11:08 ET | 543 | 4.38 |
| 11:11 ET | 200 | 4.36 |
| 11:15 ET | 379 | 4.37 |
| 11:18 ET | 100 | 4.37 |
| 11:20 ET | 700 | 4.3693 |
| 11:24 ET | 100 | 4.36 |
| 11:26 ET | 100 | 4.365 |
| 11:27 ET | 185 | 4.365 |
| 11:31 ET | 100 | 4.37 |
| 11:33 ET | 1000 | 4.3799 |
| 11:38 ET | 200 | 4.37 |
| 11:42 ET | 200 | 4.37 |
| 11:44 ET | 1286 | 4.37 |
| 11:54 ET | 300 | 4.38 |
| 11:58 ET | 329 | 4.38 |
| 12:00 ET | 225 | 4.38 |
| 12:03 ET | 1996 | 4.37 |
| 12:05 ET | 600 | 4.38 |
| 12:07 ET | 833 | 4.375 |
| 12:09 ET | 100 | 4.37 |
| 12:12 ET | 1751 | 4.36 |
| 12:14 ET | 1471 | 4.3416 |
| 12:18 ET | 400 | 4.34 |
| 12:20 ET | 234 | 4.33 |
| 12:23 ET | 200 | 4.3383 |
| 12:27 ET | 644 | 4.3302 |
| 12:30 ET | 100 | 4.33 |
| 12:32 ET | 1346 | 4.3488 |
| 12:34 ET | 100 | 4.34 |
| 12:36 ET | 2700 | 4.34 |
| 12:38 ET | 400 | 4.34 |
| 12:39 ET | 899 | 4.34 |
| 12:41 ET | 445 | 4.3532 |
| 12:43 ET | 200 | 4.38 |
| 12:54 ET | 510 | 4.37 |
| 12:57 ET | 200 | 4.38 |
| 01:06 ET | 100 | 4.39 |
| 01:10 ET | 500 | 4.38 |
| 01:14 ET | 150 | 4.3701 |
| 01:15 ET | 100 | 4.37 |
| 01:17 ET | 3844 | 4.41 |
| 01:30 ET | 100 | 4.39 |
| 01:35 ET | 111 | 4.398 |
| 01:37 ET | 501 | 4.4 |
| 01:48 ET | 800 | 4.4 |
| 01:50 ET | 159 | 4.3947 |
| 01:53 ET | 345 | 4.4 |
| 02:06 ET | 600 | 4.4099 |
| 02:11 ET | 200 | 4.4 |
| 02:13 ET | 400 | 4.4 |
| 02:18 ET | 100 | 4.43 |
| 02:20 ET | 600 | 4.41 |
| 02:22 ET | 100 | 4.3977 |
| 02:29 ET | 100 | 4.405 |
| 02:33 ET | 100 | 4.42 |
| 02:36 ET | 200 | 4.42 |
| 02:38 ET | 139 | 4.42 |
| 02:40 ET | 145 | 4.43 |
| 02:42 ET | 359 | 4.43 |
| 02:44 ET | 100 | 4.41 |
| 02:45 ET | 100 | 4.42 |
| 02:47 ET | 100 | 4.42 |
| 02:54 ET | 12973 | 4.3924 |
| 02:56 ET | 100 | 4.4 |
| 02:58 ET | 1466 | 4.43 |
| 03:00 ET | 460 | 4.4 |
| 03:02 ET | 1700 | 4.4001 |
May 7, 2024
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference, from 8:30AM ET on Tuesday May 07, 2024 by Dow Jones
8:30AM ET on Tuesday May 07, 2024 by Dow Jones
Apr 25, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vistagen Therapeutics Inc | 121.1M | -1.2x | --- |
aTyr Pharma Inc | 118.7M | -1.9x | --- |
DiaMedica Therapeutics Inc | 123.4M | -5.2x | --- |
Vigil Neuroscience Inc | 123.5M | -1.5x | --- |
Vor Biopharma Inc | 123.5M | -1.0x | --- |
Nuvectis Pharma Inc | 117.2M | -4.4x | --- |
Company Information
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.
Contact Information
- Headquarters
- 343 ALLERTON AVENUESOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-577-3600
- Fax
- ---
Executives
- Independent Chairman of the Board
- Jon Saxe
- Chief Executive Officer, Director
- Shawn Singh
- Chief Financial Officer
- Cynthia Anderson
- Chief Operating Officer
- Joshua Prince
- Chief Corporate Development Officer and General Counsel
- Reid Adler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $121.1M |
|---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 27.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $-3.56 |
Book Value | $1.65 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 116.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,252.53% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
